NPPA panel pegs price of Hetero Labs HIV drug Darunavir Ethanolate at Rs 190.44 per tablet
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) Committee has suggested the retail price of each film-coated tablet containing Darunavir Ethanolate, which is equivalent to Darunavir IP 800 mg plus Ritonavir IP 100 mg, at Rs. 190.44 per tablet excluding GST, manufactured by Hetero Labs Ltd. and marketed by Cipla Ltd.
This came after the Multidisciplinary Committee of Experts deliberated on the retail price fixation of the popular protease inhibitor Darunavir Ethanolate, which is used to treat HIV.
Darunavir Ethanolate is the ethanolate form of darunavir, which is a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor. Darunavir, in general, is used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection.
Darunavir specifically targets and binds to the active site of HIV-1 protease after oral administration, inhibiting dimerization and catalytic activity of HIV-1 protease.In HIV-infected cells, this suppresses the proteolytic cleavage of viral Gag and Gag-Pol polyproteins. This suppression results in the synthesis of immature, non-infectious viral proteins that are unable to form mature virions and prevents HIV replication.
After detailed deliberation, the committee recommended the retail price of each film-coated tablet containing Darunavir Ethanolate eq. to Darunavir IP 800 mg + Ritonavir IP 100 mg for M/s Hetero Labs Ltd. (manufacturer) and M/s Cipla Ltd. (marketer) at Rs. 190.44 per tablet excluding GST as detailed below:
Price To Retailer (PTR) as per Fom-V submitted by the company
PTR per tablet
Hetero Healthcare Ltd
Rs. 5109.29 per 30 tablet
Emcure Pharmaceuticals Ltd
Rs. 4741.20 per 30 tablet
Therefore, average PTR
Add: 16% retailer margin
Worked out the retail price per tablet